Negative Selection of Human Germinal Center B Cells by Prolonged BCR Cross-linking
Overview
General Medicine
Authors
Affiliations
The antigen receptors on T and B lymphocytes can transduce both agonist and antagonist signals leading either to activation/survival or anergy/death. The outcome of B lymphocyte antigen receptor (BCR) triggering depends upon multiple parameters which include (a) antigen concentration and valency, (b) duration of BCR occupancy, (c) receptor affinity, and (d) B cell differentiation stages. Herein, using anti-immunoglobulin kappa and lambda light chain antibodies, we analyzed the response of human naive, germinal center (GC) or memory B cells to BCR cross-linking regardless of heavy chain Ig isotype or intrinsic BCR specificity. We show that after CD40-activation, anti-BCR (kappa + gamma) can elicit an intracellular calcium flux on both GC and non-GC cells. However, prolonged BCR cross-linking induces death of CD40-activated GC B cells but enhances proliferation of naive or memory cells. Anti-kappa antibody only kills kappa + GC B cells without affecting surrounding gamma + GC B cells, thus demonstrating that BCR-mediated killing of GC B lymphocytes is a direct effect that does not involve a paracrine mechanism. BCR-mediated killing of CD40-activated GC B cells could be partially antagonized by the addition of IL-4. Moreover, in the presence of IL-4, prestimulation through CD40 could prevent subsequent anti-Ig-mediated cell death, suggesting a specific role of this combination in selection of GC B cells. This report provides evidence that in human, susceptibility to BCR killing is regulated along peripheral B cell differentiation pathway.
Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.
Hu Y, Li Q, Wang P, Li X, Hu Z Front Oncol. 2023; 13:1140813.
PMID: 37182123 PMC: 10172652. DOI: 10.3389/fonc.2023.1140813.
Berry C, Liu X, Myles A, Nandi S, Chen Y, Hershberg U Cell Rep. 2020; 31(2):107474.
PMID: 32294437 PMC: 7301411. DOI: 10.1016/j.celrep.2020.03.038.
Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
Salazar-Fontana L, Desai D, Khan T, Pillutla R, Prior S, Ramakrishnan R AAPS J. 2017; 19(2):377-385.
PMID: 28083796 DOI: 10.1208/s12248-016-0030-z.
Colombo M, Cutrona G, Reverberi D, Bruno S, Ghiotto F, Tenca C Mol Med. 2013; 19:294-302.
PMID: 23877718 PMC: 4344459. DOI: 10.2119/molmed.2013.00069.
Cellular choreography in the germinal center: new visions from in vivo imaging.
Hauser A, Kerfoot S, Haberman A Semin Immunopathol. 2010; 32(3):239-55.
PMID: 20614218 PMC: 3659422. DOI: 10.1007/s00281-010-0214-z.